NEW ORLEANS, Sept. 08, 2017 -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until October 27, 2017 to file lead plaintiff applications in a securities class action lawsuit against Vitamin Shoppe, Inc. (NYSE:VSI), if they purchased the Company’s shares between the expanded period of March 1, 2017 and August 8, 2017, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of New Jersey.
Get Help
Vitamin Shoppe investors should visit us at https://www.claimsfiler.com/cases/nasdaq-vsi or call to speak to our claim center toll-free at (844) 367-9658.
About the Lawsuit
Vitamin Shoppe and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On March 1, 2017, Vitamin Shoppe announced that it expected to deliver “[f]ully diluted earnings per share in the range of $1.95 - $2.20” during fiscal year 2017. Subsequently, on May 10, 2017, the Company slashed FY17 guidance by more than 45% and then on August 9, 2017, revealed it was taking a goodwill impairment charge of $168 million and as a result, a GAAP loss per share of $6.73 in 2Q17.
On this news, the price of Vitamin Shoppe’s shares plummeted.
About ClaimsFiler
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. ClaimsFiler's team of experts monitor the securities class action landscape and cull information from a variety of sources to ensure comprehensive coverage across a broad range of financial instruments.
To learn more about ClaimsFiler, visit www.claimsfiler.com.


Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 



